Core Insights - AstraZeneca has announced a strategic partnership with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [2][3] Group 1: Partnership Details - The collaboration focuses on developing innovative long-acting peptide drugs using CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform [2] - CSPC's long-acting technology allows for monthly or longer dosing intervals, enhancing patient compliance for long-term medication [2] - The partnership includes the overseas rights for a weight management product, SYH2082, which is a long-acting GLP-1R/GIPR agonist currently advancing to Phase I clinical trials, along with three preclinical projects targeting obesity and weight-related issues [2][3] Group 2: Financial Implications - CSPC will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion for sales, plus a double-digit percentage royalty on net sales of the licensed products [3] - The global competition in GLP-1 development has intensified, with pharmaceutical companies focusing on next-generation weight loss therapies that improve patient experience and efficacy [3] Group 3: Previous Collaborations - This is not the first collaboration between AstraZeneca and CSPC; they previously established a partnership in June 2025 with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [4] - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its presence in drug production and R&D [4]

（股份代號：1093） （於香港註冊成立之有限公司） 自願公告 與阿斯利康就創新長效多肽藥物開發簽訂戰略合作與授權協議 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團已與全球生物製藥領導者阿斯利康簽訂戰略研發合作與授權協議（「該協議」）， 以利用本集團專有的緩釋給藥技術平台及多肽藥物AI發現平台（「該等平台」），開發創新長 效多肽藥物。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 – 2 – – 1 – 除中國內地、香港特別行政區、澳門特別行政區及台灣地區外，阿斯利康將獲得本集團每 月一次注射用體重管理產品組合的全球獨家權利，包括一個臨床準備就緒的項目SYH2082 （ 長效GLP1R / GIPR激動劑，正推進至I期臨床 ），以及三 ...